Abstract
Clinical transplantation requires nonspecific immunosuppressive agents to prevent graft rejection. The use of such agents decrease morbidity and mortality from its associated side effects. Therefore, clinical application of the donor-specific tolerance is needed. We have proposed two transplantation tolerance systems. One is drug-induced tolerance and the other is monoclonal antibody-induced tolerance system. In this article, we reviewed our own donor-specific transplantation tolerance systems and argue its possibility of clinical application.
